Advances in molecular pathology and therapy of non-small cell lung cancer.

240 Secondly, there is now an increasing trend toward using short-term survival endpoints such as PFS as surrogates for drug efficacy assessment, but this is a double-edged sword. 456 The advantage is that it accelerates drug approval and reduces development costs, but critics argue that there is no inherent link between PFS and OS determination, and that tumors may later accelerate growth due to resistance, making up for previous deficits.

also in 63,971 other papers